Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned

American Journal of Roentgenology

Volumn 188, Issue 2, 2007, Pages 586-592

  Broome, Dale R ^a   Girguis, Mark S ^a   Baron, Pedro W ^a   Cottrell, Alfred C ^a   Kjellin, Ingrid ^a   Kirk, Gerald A ^a  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dialysis; MR contrast agents; MR imaging; Nephrogenic systemic fibrosis; Nuclear medicine; Renal disease

Indexed keywords

GADODIAMIDE;

ADULT; BONE SCINTISCANNING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMORBIDITY; CONTRAST ENHANCEMENT; DRUG EXPOSURE; DRUG UPTAKE; EDEMA; FASCIA; FEMALE; HEPATORENAL SYNDROME; HUMAN; IMAGE ANALYSIS; KIDNEY FAILURE; LABORATORY DIAGNOSIS; MALE; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOLOGIST; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; REVIEW; RISK; RISK FACTOR; SINGLE DRUG DOSE; SKIN EDEMA; SKIN FIBROSIS;

ADULT; CALIFORNIA; CAUSALITY; COMORBIDITY; FEMALE; FIBROSIS; GADOLINIUM DTPA; HUMANS; INCIDENCE; KIDNEY FAILURE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SKIN DISEASES;

EID: 33846541879     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.06.1094     Document Type: Review

References (21)

1. Cowper SE, Robin HS, Steinberg HM, Su LD, Gupta S, Leboit PE. Scleromyxedema-like cutaneous disease in renal-dialysis patients. Lancet 2000; 356:1000-1001
2. Cowper SE. Nephrogenic fibrosing dermopathy [NFD/NSF] Web site, 2001-2006. Available at http://www.icnfdr.org. Last accessed June 8, 2006
3. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy; an autopsy case and review of the literature. Arch Path Lab Med 2006; 130:209-212
4. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005; 46:763-765
5. Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 2003; 25:204-209
6. Gremmels JM, Kirk GA. Two patients with abnormal muscle uptake of Tc-99m hydroxymethylene diphosphonate following liver transplant: nephrogenic fibrosing dermopathy and graft vs host disease. Clin Nucl Med 2004; 29:694-697
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41
8. LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol 2003; 139:928-930
9. U.S. Food and Drug Administration. Public health advisory: Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. June 8,2006. Available at: http://www.fda.gov/cder/ drug/advisory/gadolinium_agents.htm Last accessed November 30, 2006
10. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1104-1108
11. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17:2359-2362
12. Cowper SE, Bucala R, Leboit PE. Editorial: nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis-setting the record straight. Semin Arthritis Rheum 2006; 4:208-210
13. DeHoratius DM, Cowper SE. Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial 2006; 19:191-194
14. Svaland MG, Lundby B, Kristofferson DT. Comparison of the safety of the standard dose and a higher dose of gadodiamide injection for MR imaging of the central nervous system. J Magn Reson Imaging 1994; 4:419-423
15. Johnson DB, Lerner CA, Prince MR, et al. Gadolinium-enhanced magnetic resonance angiography of renal transplants. Magn Reson Imaging 1997; 15:13-20
16. Prince MR, Erel HE, Lent RW, et al. Gadodiamide administration causes spurious hypocalcemia. Radiology 2003; 227:639-646
17. Uggeri F, Aime S, Anelli PL, et al. Novel contrast agents for magnetic resonance imaging. Synthesis and characterisation of the ligand BOPTA and its Ln(III) complexes. Inorg Chem 1995; 34:633-642
18. Prince MR, Arnoldus C, Frisoli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging 1996; 6:162-166
19. Thomsen HS. Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol 2004; 14:1654-1656
20. Maloo M, Abt P, Kashyap R, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006; 6:2212-2217
21. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acta Radiol 1998; 5:491-502